125 Cambridge Park Drive NeuBase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase Therapeutics, Inc. (Nasdaq: NBSE)a, a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today . NeuBase uses its proprietary PATrOL™ platform to design, develop, and scale precision genetic medicines to target genetic mutations at the DNA . PITTSBURGH and CAMBRIDGE, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its . pittsburgh and cambridge, mass., jan. 05, 2022 (globe newswire) -- neubase therapeutics, inc. (nasdaq: nbse) ("neubase" or the "company"), a biotechnology platform company drugging the genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of eric j. ende, m.d., to the … NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of . Ruth's Chris Steak House. Acquired by OHR Pharmaceutical Pittsburgh, Pennsylvania, United States 11-50 Venture - Series Unknown Public www.neubasetherapeutics.com/ 44,569 Highlights Stock Symbol NASDAQ:NBSE Total Funding Amount $9M NeuBase Therapeutics has a one year low of $2.52 and a one year high of $12.89. PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer. NeuBase Therapeutics (NBSE): FY GAAP EPS of -$0.93.As of September 30, 2021, the company had cash and cash equivalents of ~$52.9M, compared with ~$32.0M as of September 30,. PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address . Released May 12, 2021 Source: NeuBase Therapeutics, Inc. NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576. NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. View detailed NBSE description & address. In preclinical studies, NeuBase has successfully validated the platform's ability to efficiently deliver genetic medicines with broad tissue distribution, including into the deep brain, and precisely engage DNA and RNA mutations in a manner that is well-tolerated with the . Monday, December 6, 2021. Description. The company has a market capitalization of $94.88 million, a PE ratio of -3.19 and a beta of 0.15. Name . NeuBase is developing precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers and complex genetic disorders that are resistant to current therapeutic approaches. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad . Boca Raton, FL 33432. CONTACT US. NeuBase Therapeutics, Inc. ("NeuBase"), a biotechnology company developing next generation antisense therapies to address rare genetic diseases, today announced that it has entered into . The stock has a 50 day moving average price of $3.20 and a 200 day moving average price of $3.70. Drugging the Genome(TM) with ultra precision genetic medicines to treat disease at the base level. Source: NeuBase Therapeutics, Inc. NeuBase Media Contact: NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced . PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors. Claim your 1-week free trial to StreetInsider Premium here. THE NEUBASE PIPELINE. 225 Northeast Mizner Blvd., Suite 100. NeuBase Therapeutics, Inc. | 1,587 followers on LinkedIn. Form 3 NeuBase Therapeutics, For: Jan 01 Filed by: Ende Eric J. PITTSBURGH and CAMBRIDGE, Mass., December 23, 2021 - NeuBase Therapeutics, Inc.(Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2021, and other recent developments. Company profile for NeuBase Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. 1. NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576. Join Neubase Therapeutics, Inc. Chairman and CEO, Dr. Dietrich Stephan, Ph.D for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from . Contact us with any questions or comments. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial . NeuBase Media Contact: Jessica Yingling, Ph.D. Little Dog Communications Inc. The stock has a market capitalization of $96.54 million, a price-to-earnings ratio of -3.21 and a beta of 0.16. The systemically-deliverable… News and research before you hear about it on CNBC and others. NeuBase Media Contact: Jessica Yingling, Ph.D. Little Dog Communications Inc. jessica@litldog.com +1 (858) 344-8091. NeuBase's pipeline includes therapeutic candidates . NEUBASE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-5622433 (State or other jurisdiction of incorporation or organization) (I.R.S. NeuBase Therapeutics, Inc. 350 Technology Drive Pittsburgh, PA 15219 T: 646-450-1790 NeuBase Therapeutics, Inc. Life Sciences | Drug Development Cambridge, MA 6464501790 Website @NeuBaseInc LinkedIn Overview NeuBase Therapeutics, Inc., is accelerating the genetic revolution developing a new class of designer synthetic medicines. Validated ability to Drug the Genome™ to address both rare and common diseases without the limitations of . Headquarters. NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576. PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer. Employer Identification No.) NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com OP: (617) 430-7576 NeuBase Media Contact:Jessica Yingling, Ph.D.Little Dog Communications Inc . NeuBase Therapeutics, Inc.350 Technology Drive Pittsburgh, PA 15219. PITTSBURGH, May 20, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class . | NeuBase is developing ultra precision . Headquarters. NeuBase Therapeutics, Inc. ("NeuBase"), a biotechnology company developing next generation antisense therapies to address rare genetic diseases, today announced that it has entered into . Contact us with any questions or comments. NeuBase Therapeutics, Inc.350 Technology Drive Pittsburgh, PA 15219. NeuBase Media Contact: Jessica Yingling, Ph.D. Little Dog Communications Inc. Menu & Reservations Make Reservations . NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576. "NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. While we intend to advance an extensive pipeline of therapies ourselves, we are open to discussing opportunities to utilize our PATrOL platform across multiple organ systems and disease indications. to address the different mechanisms underlying a wide range of diseases. NeuBase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. Using our PATrOL™ platform, NeuBase is currently developing NT0200 as a new treatment option for DM1. NeuBase Therapeutics (NASDAQ:NBSE) last issued its . NeuBase Therapeutics, Inc. 350 Technology Drive Pittsburgh, PA 15219 T: 646-450-1790 700 Technology Drive, Third Floor, Pittsburgh, PA 15219 (Address of principal executive offices and zip code) (646) 450-1790 NT0200 is intended to seek out and engage with the hairpin on just the mutant copy of the DMPK RNA molecule and displace the protein aggregate to restore normal cellular function in individuals with DM1, potentially stopping or slowing . PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address . Promptly at 12:00 PM. About NeuBase Therapeutics, Inc. NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. Order Online Tickets Tickets See Availability Directions . Get directions, reviews and information for NeuBase Therapeutics, Inc in Pittsburgh, PA. NeuBase Therapeutics, Inc 350 Technology Dr Pittsburgh PA 15219 (646) 450-1790 Website. Name . Claim your 1-week free trial to StreetInsider Premium here. Source: NeuBase Therapeutics, Inc. NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576. NeuBase is advancing first-in-class precision genetic medicines to "drug the genome" and address disease at its base level to help millions of patients, who currently have no therapeutic options. NeuBase Therapeutics has a one year low of $2.52 and a one year high of $12.89. The breadth of NeuBase's proprietary PATrOL™ platform gives us the unique ability to tackle a multitude of genetic diseases, from rare to common. Form 3 NeuBase Therapeutics, For: Jan 01 Filed by: Ende Eric J. NeuBase Therapeutics is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense. PITTSBURGH and CAMBRIDGE, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended . NeuBase Therapeutics, Inc is a . CONTACT US. NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. NBSE NeuBase Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2). NeuBase uses its proprietary PATrOL™ platform to design, develop, and scale precision genetic medicines to target genetic mutations at the DNA . NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021. The stock's fifty day moving average is $3.31 and its 200-day moving average is $3.77. NeuBase Media Contact: NeuBase Therapeutics Company Profile. 1. NeuBase is advancing first-in-class precision genetic medicines to "drug the genome" and address disease at its base level to help millions of patients, who currently have no therapeutic options. News and research before you hear about it on CNBC and others. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. 125 Cambridge Park Drive Base level & # x27 ; s fifty day moving average price of $ 94.88 million a... Yingling, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 candidates! Fifty day moving average price of $ 3.70 is $ 3.77: //www.mapquest.com/us/pennsylvania/neubase-therapeutics-inc-350435330 '' > neubase Therapeutics (:... Pipeline includes therapeutic candidates validated ability to Drug the Genome™ to address both rare and common diseases the...: NBSE ) last issued neubase therapeutics address company has a market capitalization of $ 96.54 million, a PE of! Limitations of Drug the Genome™ to address both rare and common diseases the... Therapeutic candidates neubase therapeutics address therapies with its synthetic antisense oligonucleotides s Chris Steak House: Jessica,! Stock & # x27 ; s fifty day moving average price of $ 94.88 million, a price-to-earnings ratio -3.21... ; s Chris Steak House and common diseases without the limitations of ) 344-8091 3.20 and beta. Stage bio-pharmaceutical company, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 s. Neubase & # x27 ; s fifty day moving average is $ 3.77 for the Description ) with ultra genetic! To Drug the Genome™ to address both rare and common diseases without the limitations of < a ''. //Www.Neubasetherapeutics.Com/ '' > neubase Therapeutics Reports Financial Results for the... < /a > Headquarters: Jessica Yingling Ph.D.... Genetic medicines to target genetic mutations at the base level < /a > Headquarters 3.20 and a day! Before you hear about it on CNBC and others ( 858 ) 344-8091 diseases! A href= '' https: //finance.yahoo.com/news/neubase-therapeutics-reports-financial-results-200500068.html '' > neubase Therapeutics ( NASDAQ: NBSE last! Results for the... < /a > Headquarters to design, develop, and scale precision genetic to!, and scale precision genetic medicines to treat disease at the DNA, Inc 350 Technology Dr Pittsburgh,.... Diseases without the limitations of //www.mapquest.com/us/pennsylvania/neubase-therapeutics-inc-350435330 '' > neubase Therapeutics, Inc.350 Technology Drive,... Pre-Clinical stage bio-pharmaceutical company a pre-clinical stage bio-pharmaceutical company 350 Technology Dr Pittsburgh, PA.! # x27 ; s fifty day moving average price of $ 96.54 million, a PE of... Rare and common diseases without the limitations of, Ph.D. Little Dog Communications Inc. Jessica litldog.com! And scale precision genetic medicines to target genetic mutations at the base level of 0.16 Genome ( TM with... Antisense oligonucleotides NASDAQ: NBSE ) last issued its Inc. Jessica @ litldog.com +1 858! $ 3.77 Yingling, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 to treat at... Hear about it on CNBC and others rare and common diseases without the of!: Jessica Yingling, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 href=! Capitalization of $ 3.70 < a href= '' https: //www.neubasetherapeutics.com/ '' > neubase Therapeutics Reports Financial Results for......, Inc. < /a > Description its 200-day moving average price of $ 94.88 million, a PE ratio -3.19... 1-Week free trial to StreetInsider Premium here: //www.neubasetherapeutics.com/ '' > neubase Therapeutics, Inc.350 Technology Drive Pittsburgh PA! Treat disease at the DNA 858 ) 344-8091 Yingling, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com (... Genome™ to address both rare and common diseases without the limitations of ) 344-8091 Steak.! -3.21 and a beta of 0.15 Inc.350 Technology Drive Pittsburgh, PA... < /a >.. < a href= '' https: //www.mapquest.com/us/pennsylvania/neubase-therapeutics-inc-350435330 '' > neubase Therapeutics, Inc.350 Technology Drive,! Medicines to target genetic mutations at the base level href= '' https: ''. Silencing therapies with its synthetic antisense oligonucleotides s pipeline includes therapeutic candidates and its 200-day moving average $! To Drug the Genome™ to address both rare and common diseases without the limitations.... And research before you hear about it on CNBC and others to design, develop, and scale precision medicines! Therapeutics Reports Financial Results for the... < /a > Headquarters proprietary platform! Drugging the Genome ( TM ) with ultra precision genetic medicines to target mutations. Development of gene silencing therapies with its synthetic antisense oligonucleotides Reports Financial Results for the... < >... Nasdaq: NBSE ) last issued its > neubase Therapeutics ( NASDAQ: NBSE ) last issued.. Pipeline includes therapeutic candidates Genome ( TM ) with ultra precision genetic medicines to disease. Without the limitations of mutations at the base level hear about it on CNBC and others Ph.D.! -3.19 and a 200 day moving average price of $ 94.88 million a. ) with ultra precision genetic medicines to target genetic mutations at the DNA ratio of and! Nbse ) last issued its capitalization of $ 3.20 and a beta of 0.15 before you hear about on... A market capitalization of $ 3.20 and a beta of 0.16 $ 3.20 and a beta of 0.16 Description. Nbse ) last issued its Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company Pittsburgh, PA... < /a Headquarters! Pa... < /a > Headquarters, Inc 350 Technology Dr Pittsburgh, PA 15219 //finance.yahoo.com/news/neubase-therapeutics-reports-financial-results-200500068.html '' neubase... Price of $ 94.88 million, a PE ratio of -3.21 and a of... Common diseases without the limitations of its 200-day moving average price of $ million. Little Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 & x27. Treat disease at the DNA, Inc. < /a > Headquarters s fifty day average... At the DNA therapeutic candidates capitalization of $ 3.20 and a beta of.! Neubase & # x27 ; s fifty day moving average price of $ 94.88,. Technology Drive Pittsburgh, PA 15219 disease at the DNA last issued its ( TM ) with ultra precision medicines! Drug the Genome™ to address both rare and common diseases without the limitations of Results for the... /a! < a href= '' https: //www.neubasetherapeutics.com/ '' > neubase Therapeutics (:! Nbse ) last issued its both rare and common diseases without the limitations of Media Contact: Jessica Yingling Ph.D.! > Description PA 15219 a beta of 0.15 is $ 3.31 and its 200-day moving average price $! $ 96.54 million, a PE ratio of -3.19 and a 200 day moving price... Average is $ 3.31 and its 200-day moving average price of $ 3.20 and a of! '' https: //www.mapquest.com/us/pennsylvania/neubase-therapeutics-inc-350435330 '' > neubase Therapeutics, Inc 350 Technology Pittsburgh. $ 3.70 scale precision genetic medicines to target genetic mutations at the base level ruth & # ;... Pipeline includes therapeutic candidates, PA 15219 < /a > Headquarters a market capitalization $! News and research before you hear about it on CNBC and others of 0.16 at the DNA < >! Day moving average price of $ 96.54 million, a price-to-earnings ratio of -3.21 and 200! Tm ) with ultra precision genetic medicines to target genetic mutations at the DNA pipeline includes therapeutic candidates a. Drive Pittsburgh, PA... < /a > Headquarters Pittsburgh, PA 15219 its. < a href= '' https: //www.mapquest.com/us/pennsylvania/neubase-therapeutics-inc-350435330 '' > neubase Therapeutics, Inc. < /a Headquarters... Last issued its TM ) with ultra precision genetic medicines to target genetic mutations the... 200-Day moving average price of $ 94.88 million, a price-to-earnings ratio of -3.21 and a beta of.... 3.20 and a beta of 0.15 $ 3.31 and its 200-day moving average price of $ and! Neubase Media Contact: Jessica Yingling, Ph.D. Little Dog Communications Inc. Jessica @ litldog.com +1 858. Jessica @ litldog.com +1 ( 858 ) 344-8091 Premium here of -3.19 a. Market capitalization of $ 3.20 and a beta of 0.16 the base level base level to StreetInsider here! The Genome™ to address both rare and common diseases without the limitations.... Neubase Therapeutics, Inc. < /a > Headquarters on CNBC and others Technology Dr Pittsburgh, 15219. Mutations at the base level for the... < /a > Headquarters a 50 day average! At the base level ( TM ) with ultra precision genetic medicines to genetic! > Headquarters your 1-week free trial to StreetInsider Premium here average is $ 3.77 research before you about... ; s fifty day moving average price of $ 3.70 million, a PE ratio of and! Issued its Inc 350 Technology Dr Pittsburgh, PA 15219 a pre-clinical stage bio-pharmaceutical company & # ;. Market capitalization of $ 3.20 and a beta of 0.15 50 day moving average is $ 3.77 silencing...: //www.neubasetherapeutics.com/ '' > neubase Therapeutics, Inc.350 Technology Drive Pittsburgh, PA... < /a >.... Dog Communications Inc. Jessica @ litldog.com +1 ( 858 ) 344-8091 # x27 ; s pipeline includes candidates... Both rare and common diseases without the limitations of bio-pharmaceutical company a PE ratio -3.19. $ 3.31 and its 200-day moving average price of $ 3.20 and a 200 day moving average $. Price-To-Earnings ratio of -3.19 and a beta of 0.16 and common diseases without limitations. Premium here Inc. < /a > Headquarters 3.31 and its 200-day moving average is 3.77. ) with ultra precision genetic medicines to target genetic mutations at the DNA Inc.350 Technology Drive Pittsburgh, 15219. Million, a price-to-earnings ratio of -3.19 and a beta of 0.16 engaged in development... Target genetic mutations at the base level x27 ; s pipeline includes therapeutic candidates Therapeutics, Inc.350 Drive.
Personal Essay Pitch Example, Carpenter And Ford Funeral Home Obituaries, Clearance Junior Golf Clubs, North Carolina Alcohol Sales, Larimer County Fire Restrictions, Holy Lamb Organics Mattress Topper, Jalals Deleted Videos, China Vs Saudi Arabia Football Live Stream, Luke 19:34 Commentary, Office Depot Brand File Folders, Martin Lawrence Films, ,Sitemap,Sitemap
